Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma

NCT01976208 ↗

Phase 2/3 Completed 630 enrolled Shanghai Zhangjiang Biotechnology Limited Company

RandomizedParallel-groupDouble-blindTreatment

Summary

The primary purpose is to evaluate the safety and efficacy of recombinant humanized anti-IgE monoclonal antibody injection in patients with allergic asthma.

Timeline

Start: 2010-12
Primary completion: 2015-12
Completion: 2015-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Omalizumab	Monoclonal antibody	—	Subcutaneous

Safety and Efficacy Study of Omalizumab to Treat Allergic Asthma

Summary

Timeline

Drugs

Indications